Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Abstract

Pituitary apoplexy is a rare and life-threatening clinical condition caused by hemorrhage and/or infarction of the pituitary gland or adenoma. Although pituitary apoplexy is usually spontaneous, it has been associated with numerous precipitating factors, such as bromocriptine use. However, reports of pituitary apoplexy during cabergoline therapy are scarce. We report three patients with cystic macroprolactinomas who developed pituitary apoplexy during cabergoline treatment.

• Authors: Giovanna Aparecida Balarini Lima, Evelyn de Oliveira Machado, Cintia Marques Dos Santos Silva, Paulo Niemeyer Filho, Mônica Roberto Gadelha
• Journal: Pituitary (Pituitary) Vol. 11 Issue 3 Pg. 287-92 ( 2008) ISSN: 1386-341X [Print] United States
• PMID: 17570067 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Dopamine Agonists
• Ergolines
• Cabergoline

Topics

• Adolescent
• Adult
• Antineoplastic Agents (adverse effects)
• Cabergoline
• Dopamine Agonists (adverse effects)
• Ergolines (adverse effects)
• Fatal Outcome
• Female
• Humans
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Pituitary Apoplexy (chemically induced, pathology)
• Pituitary Neoplasms (drug therapy, pathology)
• Prolactinoma (drug therapy, pathology)
• Tomography, X-Ray Computed